Alteraciones endocrino-metabólicas inducidas por bexaroteno en el tratamiento del linfoma cutáneo de células T

Bexarotene treatment in patients with CTCL produces endocrinemetabolic alterations such as central hypothyroidism and mixed dyslipidemia, which usually require treatment with additional doses of levothyroxine and lipidlowering agents. These changes are reversible after discontinuing the drug.